01/27/2022 – 23:22
MitoSense, Inc.
GREAT FALLS, Va., April 20 /PRNewswire/
The US company is initially concentrating on research into ALS
MitoSense, Inc., a life sciences company focused on harnessing the power of mitochondria to treat disease, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US Department of Veterans Affairs (VA) has closed.
With its exclusively licensed and patent-pending Mitochondrial Organelle Transplantation (MOTTM ) technology, in which mitochondria are donated to treat disease, MitoSense aims to provide better treatment options for people with neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s.
A priority for CRADA is the analysis of mitochondrial transplantation studies to determine outcomes and implications for disease. Researchers will also collect clinical trials on ALS, primarily focusing on therapeutic approaches to determine outcomes, analyze biomarkers and measure treatment effectiveness. In addition, researchers will develop an Institutional Review Board (IRB) protocol for a retrospective study of all ALS patients in the VA.
Most importantly, the agreement with the VA will allow scientists to evaluate the use of machine learning and artificial intelligence in developing algorithms suitable for diagnosing and assessing the progression of ALS. The scientists from the VA and MitoSense will also develop concepts for a prospective study for ALS patients in the VA in order to further evaluate the algorithms.
According to a 2015 study by researchers at the Harvard School of Public Health, US veterans are nearly 60% more likely to develop Lou Gehrig’s disease (also known as ALS) than the general population.
“In the VA we find exactly the target group that our physicians and scientists want to work with in the fight against ALS,” said MitoSense CEO Van Hipp National Polytrauma Center is the VA and treats the most ALS patients in the entire VA system.”
dr Charles Brock, MD, Chief of Neurology at James A. Haley Veterans’ Hospital said, “ALS and other neurodegenerative diseases are devastating diseases. Few therapies are available to us to slow its progression, let alone attempt a cure. The benefit that can theoretically be achieved from the mitochondrial transplant gives us hope to slow disease progression and improve patient capacity. Investigating the physiological benefits of this therapy and the underlying mechanisms of action is a new way of applying this treatment. We are excited to be collaborating on this project for the benefit of veterans and all patients with these otherwise devastating diseases.”
dr Steven Scott, DO, Chief of Physical Medicine and Rehabilitation and Medical Director of the Polytrauma Rehabilitation Center at James A. Haley Veterans’ Hospital also noted that “Veterans who fought for our freedom are now suffering from ALS, thanks to this research may be able to regain more independence in their daily lives.”
Further work on ALS is planned in future phases of CRADA.
Information about MitoSense
MitoSense is a private research and development company focused on harnessing the power of mitochondria to treat diseases, particularly neurodegenerative diseases. The company utilizes an exclusively licensed technology to deliver human mitochondria via mitochondrial organelle transplant (MOTTM) and is initially directing its efforts through its US-based research partner to the treatment of amyotrophic lateral sclerosis (ALS). For more information, see: MitoSense Inc.com.
Logo – https://mma.prnewswire.com/media/1735129/Logo_with_name_Logo.jpg
Press contact:
Charles Harvey,
703-309-6948,
[email protected]
Original content by: MitoSense, Inc., transmitted by news aktuell